Literature DB >> 23318932

Familial hypertrophic cardiomyopathy: functional effects of myosin mutation R723G in cardiomyocytes.

Theresia Kraft1, E Rosalie Witjas-Paalberends, Nicky M Boontje, Snigdha Tripathi, Almuth Brandis, Judith Montag, Julie L Hodgkinson, Antonio Francino, Francisco Navarro-Lopez, Bernhard Brenner, Ger J M Stienen, Jolanda van der Velden.   

Abstract

Familial Hypertrophic Cardiomyopathy (FHC) is frequently caused by mutations in the β-cardiac myosin heavy chain (β-MyHC). To identify changes in sarcomeric function triggered by such mutations, distinguishing mutation effects from other functional alterations of the myocardium is essential. We previously identified a direct effect of mutation R723G (MyHC723) on myosin function in slow Musculus soleus fibers. Here we investigate contractile features of left ventricular cardiomyocytes of FHC-patients with the same MyHC723-mutation and compare these to the soleus data. In mechanically isolated, triton-permeabilized MyHC723-cardiomyocytes, maximum force was significantly lower but calcium-sensitivity was unchanged compared to donor. Conversely, MyHC723-soleus fibers showed significantly higher maximum force and reduced calcium-sensitivity compared to controls. Protein phosphorylation, a potential myocardium specific modifying mechanism, might account for differences compared to soleus fibers. Analysis revealed reduced phosphorylation of troponin I and T, myosin-binding-protein C, and myosin-light-chain 2 in MyHC723-myocardium compared to donor. Saturation of protein-kinaseA phospho-sites led to comparable, i.e., reduced MyHC723-calcium-sensitivity in cardiomyocytes as in M. soleus fibers, while maximum force remained reduced. Myofibrillar disarray and lower density of myofibrils, however, largely account for reduced maximum force in MyHC723-cardiomyocytes. The changes seen when phosphorylation of sarcomeric proteins in myocardium of affected patients is matched to control tissue suggest that the R723G mutation causes reduced Ca(++)-sensitivity in both cardiomyocytes and M. soleus fibers. In MyHC723-myocardium, however, hypophosphorylation can compensate for the reduced calcium-sensitivity, while maximum force generation, lowered by myofibrillar deficiency and disarray, remains impaired, and may only be compensated by hypertrophy.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23318932     DOI: 10.1016/j.yjmcc.2013.01.001

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  30 in total

Review 1.  Research priorities in sarcomeric cardiomyopathies.

Authors:  Jolanda van der Velden; Carolyn Y Ho; Jil C Tardiff; Iacopo Olivotto; Bjorn C Knollmann; Lucie Carrier
Journal:  Cardiovasc Res       Date:  2015-01-28       Impact factor: 10.787

Review 2.  Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy.

Authors:  Ali J Marian; Eugene Braunwald
Journal:  Circ Res       Date:  2017-09-15       Impact factor: 17.367

3.  Hypertrophic Cardiomyopathy: A Vicious Cycle Triggered by Sarcomere Mutations and Secondary Disease Hits.

Authors:  Paul J M Wijnker; Vasco Sequeira; Diederik W D Kuster; Jolanda van der Velden
Journal:  Antioxid Redox Signal       Date:  2018-04-11       Impact factor: 8.401

4.  Preserved cross-bridge kinetics in human hypertrophic cardiomyopathy patients with MYBPC3 mutations.

Authors:  Sabine J van Dijk; Nicky M Boontje; Martijn W Heymans; Folkert J Ten Cate; Michelle Michels; Cris Dos Remedios; Dennis Dooijes; Marjon A van Slegtenhorst; Jolanda van der Velden; Ger J M Stienen
Journal:  Pflugers Arch       Date:  2013-11-02       Impact factor: 3.657

Review 5.  Targets for therapy in sarcomeric cardiomyopathies.

Authors:  Jil C Tardiff; Lucie Carrier; Donald M Bers; Corrado Poggesi; Cecilia Ferrantini; Raffaele Coppini; Lars S Maier; Houman Ashrafian; Sabine Huke; Jolanda van der Velden
Journal:  Cardiovasc Res       Date:  2015-01-29       Impact factor: 10.787

6.  Molecular Genetic Basis of Hypertrophic Cardiomyopathy.

Authors:  A J Marian
Journal:  Circ Res       Date:  2021-05-13       Impact factor: 17.367

7.  Faster cross-bridge detachment and increased tension cost in human hypertrophic cardiomyopathy with the R403Q MYH7 mutation.

Authors:  E Rosalie Witjas-Paalberends; Claudia Ferrara; Beatrice Scellini; Nicoletta Piroddi; Judith Montag; Chiara Tesi; Ger J M Stienen; Michelle Michels; Carolyn Y Ho; Theresia Kraft; Corrado Poggesi; Jolanda van der Velden
Journal:  J Physiol       Date:  2014-06-13       Impact factor: 5.182

8.  Cardiomyopathy mutations impact the actin-activated power stroke of human cardiac myosin.

Authors:  Wanjian Tang; Jinghua Ge; William C Unrath; Rohini Desetty; Christopher M Yengo
Journal:  Biophys J       Date:  2021-04-20       Impact factor: 3.699

Review 9.  Muscle dysfunction in hypertrophic cardiomyopathy: what is needed to move to translation?

Authors:  Corrado Poggesi; Carolyn Y Ho
Journal:  J Muscle Res Cell Motil       Date:  2014-02-04       Impact factor: 2.698

10.  Why make a strong muscle weaker?

Authors:  Bogdan Iorga; Theresia Kraft
Journal:  J Gen Physiol       Date:  2021-06-09       Impact factor: 4.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.